Effect of Rosiglitazone on N-nitroso-N-methylurea-induced Mammary Tumors in Rat.

MARIEL NÚÑEZ; GABRIELA MARTIN; CLAUDIA COCCA; NORA MOHAMAD; ALICIA GUTIÉRREZ; GRACIELA CRICCO; VANINA MEDINA; ELENA RIVERA; MÁXIMO CROCI; ERNESTO CRESCENTI; ROSA BERGOC

ANTICANCER RESEARCH

J.G. Delinassios, Institute of Anticancer Research

Lugar: Athens; Año: 2006 vol. 26 p. 2113 - 2122

0250-7005

The objective of this study was to evaluate the invivo antitumor action of rosiglitazone (Rosi) alone or incombination with tamoxifen (Tam) on experimental mammarytumors induced by N-nitroso-N-methylurea (NMU) inSprague-Dawley rats. Animals bearing mammary tumors weretreated with 0.06 mg/kg/day or 0.12 mg/kg/day of Rosi orally,1 mg/kg/day of Tam s.c., or with the combined treatment(Rosi+Tam). After 25 days of treatment, the followingresponses were observed: 45% of tumors were responsive to0.06 mg/kg/day of Rosi treatment, while 55% of tumors underTam treatment responded. The results of the combinedRosi+Tam treatment indicated that 75% of tumors wereresponsive. Similar results were obtained with 0.12 mg/kg/dayof Rosi. Apoptosis, necrosis and glandular hypersecretion wereobserved in Rosi-treated tumors. In all cases, the combinedRosi+Tam treatment potentiated the antitumor effect of Tamalone. No side-effects were observed after treatment at anyassayed dose.